Poly Cystic Ovary SyndromeNCT07586969
Modulation of Hyperandrogenic Anovulation Through Fenugreek Seeds
A study testing Fenugreek seeds (G1): and Fenugreek seeds (G2) in people with Poly Cystic Ovary Syndrome, run by University of Lahore at 1 site in Pakistan.
Trial summary
Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Read more about this study
- Who is it for?
- Ages 15 to 25 years, women only
- Conditions the study is for
- Poly Cystic Ovary Syndrome
- What is being tested?
- Fenugreek seeds (G1): and Fenugreek seeds (G2)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 sitePakistan
- Study dates
- 11 Sep 2024to 11 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 25 years
- Women only
- No healthy volunteers
- Child, Adult
Who may be able to join
- Female have been BMI more than 25
- Patients with irregular periods or hormonal imbalance
- Patients with age 15 to 25 years of young females
Who cannot join
- Pregnant \& Lactating Women
- Any history of allergic reaction to fenugreek seeds
- Severe gastrointestinal disorders like crohn's disease
- People with liver or kidney issue
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Modulation of Hyperandrogenic Anovulation Through Fenugreek(Trigonella Foenum Graecum L.) Seeds Among Young Females
Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Studies indicate that fenugreek seeds have the potential to improve insulin sensitivity, control hormone levels, namely the increased androgens linked to hyperandrogenic anovulation, and promote ovulation, a process commonly interrupted in individuals with hyperandrogenic anovulation. In order to create a therapy plan that is both affordable and easily accessible for women who suffer from hyperandrogenic anovulation, this study aims to determine the therapeutic efficacy of fenugreek seed powder in reducing symptoms related to the illness. Furthermore, it aims to increase knowledge on the extensive utilization of fenugreek seed powder as a natural treatment for hyperandrogenic anovulation.
Read the detailed description
- To collect data, written consent was obtained from the hospital and university administration.
- After receiving signed informed consent, the data were collected.
- Screening: The participants who meet the study inclusion criteria were enrolled and FSH/LH, Insulin resistance or lipid profile samples were taken by the hospital lab assistant. The participants will be requested not to alter their routine physical activity.
- Allocation: Following screening, participants were divided evenly into three groups: experimental group (1, 2) and one control group. The participants received different dosage in different experimental groups of fenugreek seeds powder) c.Follow up: A systematic communication plan will be developed in order to follow up with participants on their daily consumption of the suggested fenugreek powder through telephonic conversations. For continuous assistance there was a WhatsApp group set up where members may ask issues and get help associated with hyperandrogenic anovulation. The follow up for patients were conducted every month; baseline and after 60 days. Appointments for follow-up exams were made in order to track developments, anthropometric measurements were calculated every follow up and modify the dosage as necessary. The baseline and post study test were compared to test the hypothesis.
- Conditions
- Poly Cystic Ovary Syndrome
- Being tested
- Control, Fenugreek seeds (G1):, Fenugreek seeds (G2)
- Keywords
- hyperandrogenic Anovulation., Fenugreek (Trigonella foenum-graecum L.), Insulin Resistance
- Medical subject headings
- Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ControlDrug
Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months.
Fenugreek seeds (G1):Dietary supplement
Participants were advised to take 3g/half teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 month.
Fenugreek seeds (G2)Dietary supplement
Participants were advised to take 6g/one teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 months.
| Study group | Role | What they receive |
|---|---|---|
| Control group | Active comparator | • Control group (G0): Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast prescribed by doctor. Receives: Drug: Control |
| fenugreek seeds low dose | Experimental | 3gram/ half teaspoon fenugreek seeds powder Receives: Dietary Supplement: Fenugreek seeds (G1): |
| Fenugreek seeds high dose | Experimental | 6gram/ one teaspoon fenugreek seeds Receives: Dietary Supplement: Fenugreek seeds (G2) |
What is being measured
The primary outcome is the main question the study is designed to answer.
FSH/LH Test
Ratio of Follicle Stimulating Hormone (FSH) to Luteinizing Hormone (LH)
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start11 Sep 2024
- Primary completion11 Nov 2024
- Study completion11 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Poly Cystic Ovary SyndromeStudies of the same condition, open and under way.
- More trials run by University of LahoreThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized Controlled Trial
- Masking
- None (open label)
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Lahore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maria Aslam, University of Lahore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07586969
- Sponsor's protocol ID
- IRB-UOL-FAHS/930/2023
- Status last verified
- May 2026
- First submitted
- 31 Jul 2025
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes
Publications
Swaroop A, Jaipuriar AS, Gupta SK, Bagchi M, Kumar P, Preuss HG, Bagchi D. Efficacy of a Novel Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS). Int J Med Sci. 2015 Oct 3;12(10):825-31. doi: 10.7150/ijms.13024. eCollection 2015.
PubMed 26516311
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Modulation of Hyperandrogenic Anovulation Through Fenugreek(Trigonella Foenum Graecum L.) Seeds Among Young Females
- ClinicalTrials.gov ID
- NCT07586969
- Acronym / sponsor ID
- IRB-UOL-FAHS/930/2023
- Conditions
- Poly Cystic Ovary Syndrome
- Keywords
- hyperandrogenic Anovulation., Fenugreek (Trigonella foenum-graecum L.), Insulin Resistance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- University of LahoreUniversity, hospital or other
- Study start
- 11 Sep 2024 (actual)
- Primary completion
- 11 Nov 2024 (actual)
- Study completion
- 11 Dec 2024 (actual)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Hyperandrogenic anovulation is a common gynecological illness that impacts the ovaries, vagina and uterus. According to Statistics, in Pakistan 17.6% of individuals seeking treatment at infertility clinics were found to be affected by hyperandrogenic anovulation. Studies indicate that fenugreek seeds have the potential to improve insulin sensitivity, control hormone levels, namely the increased androgens linked to hyperandrogenic anovulation, and promote ovulation, a process commonly interrupted in individuals with hyperandrogenic anovulation. In order to create a therapy plan that is both affordable and easily accessible for women who suffer from hyperandrogenic anovulation, this study aims to determine the therapeutic efficacy of fenugreek seed powder in reducing symptoms related to the illness. Furthermore, it aims to increase knowledge on the extensive utilization of fenugreek seed powder as a natural treatment for hyperandrogenic anovulation.
Detailed description
- To collect data, written consent was obtained from the hospital and university administration.
- After receiving signed informed consent, the data were collected.
- Screening: The participants who meet the study inclusion criteria were enrolled and FSH/LH, Insulin resistance or lipid profile samples were taken by the hospital lab assistant. The participants will be requested not to alter their routine physical activity.
- Allocation: Following screening, participants were divided evenly into three groups: experimental group (1, 2) and one control group. The participants received different dosage in different experimental groups of fenugreek seeds powder) c.Follow up: A systematic communication plan will be developed in order to follow up with participants on their daily consumption of the suggested fenugreek powder through telephonic conversations. For continuous assistance there was a WhatsApp group set up where members may ask issues and get help associated with hyperandrogenic anovulation. The follow up for patients were conducted every month; baseline and after 60 days. Appointments for follow-up exams were made in order to track developments, anthropometric measurements were calculated every follow up and modify the dosage as necessary. The baseline and post study test were compared to test the hypothesis.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Randomized Controlled Trial
| Arm | Type | Receives |
|---|---|---|
| Control group | Active comparator | Drug: Control• Control group (G0): Participants were only subjected to use Glucophage 500mg 30 minutes before breakfast prescribed by doctor. |
| fenugreek seeds low dose | Experimental | Dietary Supplement: Fenugreek seeds (G1):3gram/ half teaspoon fenugreek seeds powder |
| Fenugreek seeds high dose | Experimental | Dietary Supplement: Fenugreek seeds (G2)6gram/ one teaspoon fenugreek seeds |
Who may qualify
- Ages
- 15 to 25 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Female have been BMI more than 25
- Patients with irregular periods or hormonal imbalance
- Patients with age 15 to 25 years of young females
Key exclusion criteria (4 listed)
- Pregnant \& Lactating Women
- Any history of allergic reaction to fenugreek seeds
- Severe gastrointestinal disorders like crohn's disease
- People with liver or kidney issue
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ControlParticipants were only subjected to use Glucophage 500mg 30 minutes before breakfast for the duration of 02 months. | Drug | Control group |
| Fenugreek seeds (G1):Participants were advised to take 3g/half teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 month. | Dietary supplement | fenugreek seeds low dose |
| Fenugreek seeds (G2)Participants were advised to take 6g/one teaspoon fenugreek seeds powder 30 minutes before breakfast for the duration of 02 months. | Dietary supplement | Fenugreek seeds high dose |
Primary outcome
FSH/LH Test
Time frame: 2 months
Ratio of Follicle Stimulating Hormone (FSH) to Luteinizing Hormone (LH)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Results publication: PubMed 26516311Swaroop A, Jaipuriar AS, Gupta SK, Bagchi M, Kumar P, Preuss HG, Bagchi D. Efficacy of a Novel Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS). Int J Med Sci. 2015 Oct 3;12(10):825-31. doi: 10.7150/ijms.13024. eCollection 2015.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes
Related trials for Poly Cystic Ovary Syndrome
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
Not yet recruiting
High Intensity Interval Training Versus Mat Pilates in Women With PCOS
Polycystic Ovarian Syndrome (PCOS), Quality of Life
Active, not recruiting
Inspiratory Muscle Training for the Management of Polyendocrine Metabolic Ovarian Syndrome
Poly Cystic Ovary Syndrome
RecruitingPhase 1
E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study
Poly Cystic Ovary Syndrome
Not yet recruitingPhase 2/3
Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome
Poly Cystic Ovary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fenugreek seeds (G1): and Fenugreek seeds (G2) in people with Poly Cystic Ovary Syndrome, run by University of Lahore at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
FSH/LH Test (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07586969, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.